Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),[1] according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA� (OROS� methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children ...

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA� (OROS� methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with ...

NEW ORLEANS, May 25 /PRNewswire/ -- Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),(1) according to the National Institute of Mental Health (NIMH).

Clinical trial in a simulated classroom "laboratory school" setting evaluated treatment efficacy on ADHD symptoms and specific challenges read more

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Paediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, to overturn a 2009 decision by the US District Court of Delaware that the patent for Concerta (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.